Rising PSA with Decreasing PSMA Uptake: Suspect PSMA-Negative Disease Progression
This discordant pattern—rising PSA but reduced PSMA uptake—strongly suggests the emergence of PSMA-negative or poorly-PSMA-expressing disease, which represents aggressive dedifferentiation and warrants immediate FDG PET/CT to identify metabolically active disease that is no longer PSMA-avid 1.
Understanding the Discordance
This PSA-PSMA mismatch is a recognized phenomenon indicating:
- Tumor dedifferentiation: Cancer cells losing PSMA expression while maintaining proliferative capacity
- Neuroendocrine differentiation: Aggressive variant that produces PSA but lacks PSMA expression
- Treatment-induced selection pressure: Particularly after PSMA-targeted radioligand therapy, where PSMA-positive clones are eliminated, allowing PSMA-negative clones to proliferate
The 2023 EANM/SNMMI guidelines acknowledge that androgen modulation can decrease PSMA uptake 2, but a rising PSA simultaneously indicates this is not treatment response—it's disease progression with phenotypic change.
Immediate Next Steps
1. Obtain FDG PET/CT Immediately
Recent 2026 evidence demonstrates that FDG PET/CT resolves PSA-PSMA discordance by revealing hypermetabolic disease that has lost PSMA expression 1. In two documented cases, FDG PET/CT identified new skeletal and visceral lesions despite apparent PSMA response, preventing futile continuation of PSMA-targeted therapy 1.
2. Discontinue PSMA-Targeted Therapy If Applicable
If the patient is receiving PSMA radioligand therapy, this discordance pattern indicates treatment failure. The 2026 data show that continuing PSMA-RLT in this setting is futile 1.
3. Assess for Neuroendocrine Differentiation
Check serum markers:
- Chromogranin A
- Neuron-specific enolase (NSE)
- Consider tissue biopsy if accessible lesions are present
Clinical Context and Pitfalls
Common Pitfall: Assuming decreased PSMA uptake represents treatment response when PSA is rising. This is incorrect—biochemical progression always trumps imaging appearance in this scenario.
Timing Consideration: The 2023 guidelines note that new androgen deprivation therapy can transiently decrease PSMA uptake 2, but this should be accompanied by falling PSA, not rising PSA. If ADT was recently initiated (within 3 months), the PSMA flare phenomenon resolves by 3 months 3, but again, PSA should be declining if treatment is effective.
Treatment Implications
Once FDG-avid disease is confirmed:
- Chemotherapy becomes the primary option: Docetaxel or cabazitaxel for FDG-positive, PSMA-negative disease
- Platinum-based regimens: If neuroendocrine features are confirmed
- Avoid further PSMA-targeted approaches: These will be ineffective against PSMA-negative clones
Prognostic Significance
The 2026 studies examining PSMA PET changes during therapy consistently show that volumetric increases and new lesions predict worse outcomes 4, 5. However, your scenario is more ominous—the disease is evolving beyond PSMA-targetable biology entirely. The emergence of PSMA-negative disease represents aggressive biology with limited treatment options and poor prognosis.
Monitoring Strategy Going Forward
- Serial FDG PET/CT becomes the primary imaging modality for response assessment
- PSA remains useful for disease monitoring despite imaging discordance
- Consider repeat PSMA PET only if contemplating re-challenge with PSMA-targeted therapy after intervening treatments
The key algorithmic decision point: Rising PSA + decreasing PSMA uptake = order FDG PET/CT immediately to identify PSMA-negative disease and guide appropriate non-PSMA-targeted systemic therapy.